作者: Olson, Jeffrey L. ; Mandava, Naresh ; Dhrami-Gavazi, Elona ; Ober, Michael D. ; Schiff, William M. ; Barile, Gaetano R. ; Chang, Stanley ; Hwang, John C.

OBJECTIVETo determine the safety and efficacy of VIT100 (Immusol, Inc, San Diego, California), a ribozyme to proliferating cell nuclear antigen, in preventing recurrent proliferative vitreoretinopathy (PVR) in patients with established PVR who undergo vitrectomy for retinal reattachment repair.METHODSA multicenter, double-masked, placebo-controlled, randomized clinical trial. One hundred seventy-five eyes from 175 patients with grade C or worse PVR were randomly assigned to receive high-dose VIT100, low-dose VIT100, or placebo by intravitreal injection at the conclusion of retinal reattachment surgery.MAIN OUTCOME MEASURESThe primary efficacy end point was recurrent retinal detachment secondary to PVR. The secondary end point was recurrent retinal detachment due to any cause.RESULTSOne hundred fifty-four patients completed the study. Forty-one patients (27%) developed recurrent retinal detachment due to PVR by 24 weeks, including 18 patients (33%) in the group receiving 0.75 mg, 13 patients (24%) in the group receiving 0.15 mg, and 10 patients (22%) in the placebo group. There was no statistically significant difference in patients reaching this end point by 24 weeks (P = .37). Ancillary statistical analyses are reported.CONCLUSIONSVIT100 was not effective in preventing PVR recurrence in patients with established grade C or worse PVR.APPLICATION TO CLINICAL PRACTICETo our knowledge, this is the most recent, meticulously designed clinical trial in PVR.

International Journal of Molecular Sciences2区 · 生物学

Changes in Metallothionein Level in Rat Hepatic Tissue after Administration of Natural Mouldy Wheat

2区 · 生物学

ArticleOA

作者: Zeman, Ladislav ; Vasatkova, Anna ; Adam, Vojtech ; Krizova, Sarka ; Kizek, Rene

Mycotoxins are secondary metabolites produced by microfungi that are capable of causing disease and death in humans and other animals. This work was aimed at investigation of influence of mouldy wheat contaminated by pathogenic fungi producing mycotoxins on metallothionein levels in hepatic tissue of rats. The rats were administrating feed mixtures with different contents of vitamins or naturally mouldy wheat for 28 days. It was found that the wheat contained deoxynivalenol (80 ± 5 µg per kg of mouldy wheat), zearalenone (56 ± 3 µg/kg), T2-toxin (20 ± 2 µg/kg) and aflatoxins as a sum of B1, B2, G1 and G2 (3.9 ± 0.2 µg/kg). Rats were fed diets containing 0, 33, 66 and 100% naturally moulded wheat. Control group 0, 33, 66 and 100% contained vitamins according to Nutrient Requirements of Rats (NRC). Other four groups (control group with vitamins, vit33, vit66 and vit100%) were fed on the same levels of mouldy wheat, also vitamins at levels 100% higher than the previous mixtures. We determined weight, feed conversion and performed dissection to observe pathological processes. Changes between control group and experimental groups exposed to influence of mouldy wheat and experimental groups supplemented by higher concentration of vitamins and mouldy wheat were not observed. Livers were sampled and did not demonstrate significant changes in morphology compared to control either. In the following experiments the levels of metallothionein as a marker of oxidative stress was determined. We observed a quite surprising trend in metallothionein levels in animals supplemented with increased concentration of vitamins. Its level enhanced with increasing content of mouldy wheat. It was possible to determine a statistically significant decline (p

100 项与 VIT-100 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05865

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤增生性瘢痕	临床1期	美国	-	-
皮肤增生性瘢痕	临床1期	-	iTherX Pharmaceuticals, Inc.	-
青光眼	临床1期	美国	iTherX Pharmaceuticals, Inc.	-
瘢痕疙瘩	临床1期	美国	-	-
瘢痕疙瘩	临床1期	-	iTherX Pharmaceuticals, Inc.	-
银屑病	临床1期	-	iTherX Pharmaceuticals, Inc.	-
银屑病	临床1期	美国	-	-
增生性玻璃体视网膜病变	临床1期	美国	iTherX Pharmaceuticals, Inc.	-